β-Lactam/β-Lactamase Inhibitor Combination Antibiotics Under Development

Area of Science:

• Infectious Diseases
• Microbiology
• Pharmacology

Background:

• Antimicrobial resistance (AMR) poses a significant global health and financial challenge.
• Multidrug-resistant (MDR) Gram-negative pathogens are a primary clinical concern.
• New β-lactam/β-lactamase inhibitor combinations offer crucial therapeutic options.

Purpose of the Study:

• To review the landscape of novel antibiotic combinations against MDR Gram-negative bacteria.
• To focus on promising combinations currently in phase 3 clinical trials.
• To discuss therapeutic advancements for infections caused by challenging pathogens.

Main Methods:

• Literature review of recent advancements in antibiotic development.
• Analysis of clinical trial progress for novel antimicrobial agents.
• Focus on combinations targeting serine and metallo-β-lactamases.

Main Results:

• Several new combinations like ceftolozane/tazobactam and ceftazidime/avibactam are approved.
• Agents targeting metallo-β-lactamase producers, such as cefiderocol, have been introduced.
• Cefepime/zidebactam, cefepime/taniborbactam, and imipenem/cilastatin/funobactam are in late-stage clinical development.

Conclusions:

• The development pipeline shows progress in addressing MDR Gram-negative infections.
• Combinations like cefepime/zidebactam, cefepime/taniborbactam, and imipenem/cilastatin/funobactam represent the next generation of treatments.
• Continued research and clinical trials are essential to combat the growing threat of antimicrobial resistance.